P. Turecek

K. Mann, L. Valentino, S. Butenas, 2018, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

Recombinant factor VIII and factor VIII-von Willebrand factor complex do not present danger signals for human dendritic cells

H. Schwarz, B. Reipert, J. Stöckl, 2006, Thrombosis and Haemostasis.

Phospholipid-bound Tissue Factor Modulates both Thrombin Generation and APC-mediated Factor Va Inactivation

V. Marder, H. Schwarz, K. Váradi, 1999, Thrombosis and Haemostasis.

Immunoadsorption for the treatment of a patient with severe thrombotic thrombocytopenic purpura resistant to plasma exchange: kinetics of an inhibitor of ADAMTS13

K. Laczika, P. Knöbl, M. Haas, 2003, Journal of thrombosis and haemostasis : JTH.

Development of a lectin binding assay to differentiate between recombinant and endogenous proteins in pharmacokinetic studies of protein-biopharmaceuticals.

A. Weber, P. Turecek, F. Scheiflinger, 2015, Journal of pharmaceutical and biomedical analysis.

a new transgenic hemophilic mouse model Maintenance and break of immune tolerance against human factor VIII in

B. Reipert, S. Unterthurner, C. Hermann, 2011 .

Deoxyribonucleic acid preparation in polymerase chain reaction genotyping of transgenic mice.

H. Schwarz, P. Turecek, K. Zimmermann, 2000, Comparative medicine.

Identification of Mutations in the Canine von Willebrand Factor Gene Associated with Type III von Willebrand Disease

J. V. van Mourik, F. Dorner, C. Mannhalter, 1998, Thrombosis and Haemostasis.

Low ADAMTS13 Activity Is a Strong Risk Factor for Ischemic Stroke: A Prospective Cohort Study - the Rotterdam Study

A. Hofman, P. Koudstaal, M. Portegies, 2014 .

Polysialic acid-mediated activity measurement of polysialylated recombinant coagulation factor VIII.

A. Weber, P. Turecek, J. Siekmann, 2020, Journal of pharmaceutical sciences.

Blockade of CD40/CD40 Ligand Interactions Prevents Induction of Factor VIII Inhibitors in Hemophilic Mice but Does not Induce Lasting Immune Tolerance

H. Schwarz, B. Reipert, R. Ahmad, 2001, Thrombosis and Haemostasis.

Biological mechanisms underlying inter‐individual variation in factor VIII clearance in haemophilia

J. Johnsen, S. Pipe, P. Turecek, 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

Effects of human recombinant, plasma-derived and porcine von Willebrand factor in pigs with severe von Willebrand disease.

M. Bonneau, F. Dorner, H. Schwarz, 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

In vivo characterization of recombinant von Willebrand factor in dogs with von Willebrand disease.

J. V. van Mourik, F. Dorner, H. Schwarz, 1997, Blood.

A world‐wide survey and field study in clinical haemostasis laboratories to evaluate FVIII:C activity assay variability of ADYNOVATE and OBIZUR in comparison with ADVATE

P. Turecek, R. Schall, D. Burger, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

ADAMTS13 autoantibody detection by quantitative immunoblotting.

H. Schwarz, K. Váradi, P. Turecek, 2003, Blood.

Origins, Development, Current Challenges and Future Directions with Activated Prothrombin Complex Concentrate for the Treatment of Patients with Congenital Haemophilia with Inhibitors

J. Oldenburg, C. Négrier, W. Schramm, 2020, Hämostaseologie.

hemophilia A with factor VIII inhibitors High-dose factor VIII inhibits factor VIII-specific memory B cells in

C. Hausl, C. Doering, H. Schwarz, 2012 .

hemophilia A with factor VIII inhibitors specific memory B cells in − High-dose factor VIII inhibits factor VIII

C. Hausl, C. Doering, H. Schwarz, 2005 .

Pro‐ and anticoagulant factors facilitate thrombin generation and balance the haemostatic response to FEIBA® in prophylactic therapy

B. Ewenstein, K. Váradi, G. Schrenk, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

Factor Eight Inhibitor Bypassing Activity

H. Schwarz, P. Turecek, 2012 .

Development of novel treatment options for patients with haemophilia

H. Ehrlich, A. Loew-Baselli, A. Gringeri, 2013, Hämostaseologie.

The biological efficacy profile of BAX 855, a PEGylated recombinant factor VIII molecule

L. Valentino, N. Hakobyan, P. Turecek, 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

Factor Xa and Prothrombin: Mechanism of Action of FEIBA

H. Schwarz, K. Váradi, P. Turecek, 1999, Vox Sanguinis.

A Fully Recombinant Partial Prothrombin Complex Effectively Bypasses fVIII In Vitro and In Vivo

F. Dorner, H. Schwarz, K. Váradi, 2002, Thrombosis and Haemostasis.

Single Cell Analysis of Factor VIII-specific T Cells in Hemophilic Mice after Treatment with Human Factor VIII

H. Schwarz, B. Reipert, R. Ahmad, 2002, Thrombosis and Haemostasis.

PEGylation or Polysialylation Reduces FVIII Binding to LRP Resulting in Prolonged Half-Life in Murine Models.

H. Ehrlich, P. Lenting, H. Schwarz, 2007 .

Long-term Persistence of Anti-factor VIII Antibody-secreting Cells in Hemophilic Mice after Treatment with Human Factor VIII

C. Hausl, F. Dorner, H. Schwarz, 2002, Thrombosis and Haemostasis.

A systematic review of physical activity in people with haemophilia and its relationship with bleeding phenotype and treatment regimen

N. O'Connell, P. Turecek, J. Gormley, 2021, Haemophilia : the official journal of the World Federation of Hemophilia.

Continuous infusion of FVIII and FIX concentrates: in vitro analysis of clinically relevant parameters

A. Schoppmann, P. Turecek, K. B. Thomas, 1999, Haemophilia : the official journal of the World Federation of Hemophilia.

Evaluation of Factor VIII Polysialylation: Identification of a Longer-Acting Experimental Therapy in Mice and Monkeys

F. Horling, B. Reipert, M. Schuster, 2019, The Journal of Pharmacology and Experimental Therapeutics.

Preclinical safety and efficacy of a new recombinant FIX drug product for treatment of hemophilia B

F. Horling, H. Schwarz, B. Dietrich, 2013, International Journal of Hematology.

Massive postoperative intramuscular bleeding in acquired von Willebrand's disease

W. Sperr, B. Meyer, I. Pabinger, 2002, Annals of Hematology.

Development of BAX 826, a Polysialylated Full-Length rFVIII with Significantly Improved PK Properties

H. Schwarz, M. Graninger, H. Rottensteiner, 2015 .

Pharmacokinetics of BAX 826, a Polysialylated Full-Length rFVIII, in Hemophilia a Mice, Rats, and Cynomolgus Monkeys

M. Wolfsegger, A. Weber, H. Rottensteiner, 2015 .

Development of a Large Scale Production Process for BAX 855, a PEGylated rFVIII Product with Prolonged Half-Life

H. Ehrlich, H. Rottensteiner, P. Turecek, 2011 .

Safety of PEGylated recombinant human full‐length coagulation factor VIII (BAX 855) in the overall context of PEG and PEG conjugates

P. Turecek, J. Siekmann, R. Stidl, 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

In Vitro and In Vivo Characterization of Full-Length rFVIII Modified with PEG Via Coupling to Primary Amino Groups.

H. Ehrlich, H. Schwarz, R. Ahmad, 2007 .

Biochemical and Functional Characterization of PEGylated rVWF.

H. Schwarz, H. P. Matthiessen, A. Weber, 2006 .

Successful treatment of patients with von Willebrand disease using a high-purity double-virus inactivated factor VIII/von Willebrand factor concentrate (Immunate).

G. Auerswald, W. Kreuz, H. Wolf, 2002, Seminars in thrombosis and hemostasis.

PEG–protein conjugates

P. Turecek, J. Siekmann, 2020 .

Structural analysis of the recombinant therapeutic product rFVIII and its PEGylated variants using 2‐D DIGE

A. Weber, H. Rottensteiner, P. Turecek, 2011, Electrophoresis.

Phenotypic Expression of Murine Hemophilia

H. Schwarz, P. Turecek, K. Zimmermann, 1999, Thrombosis and Haemostasis.

Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial.

C. Kempton, P. Mannucci, E. Romond, 2013, Blood.

Recombinant von Willebrand Factor

F. Dorner, H. Schwarz, L. Drouet, 1997, Thrombosis and Haemostasis.

PEGylated Biopharmaceuticals

B. Schweighardt, L. Tsuruda, B. Reipert, 2015, Toxicologic pathology.

Pharmacokinetics of Baxter’s Longer Acting rFVIII (BAX 855) in Factor VIII Ko Mice, Rats and Cynomolgus Monkeys

H. Ehrlich, H. Schwarz, J. Lawo, 2011 .

Recombinant von Willebrand Factor-Insight into Structure and Function through Infusion Studies in Animals with Severe von Willebrand Disease

F. Dorner, H. Schwarz, K. Váradi, 2002, Seminars in thrombosis and hemostasis.

Recombinant VWF Promotes Platelet Adhesion Under Shear Stress Dependent on Its Multimer Size

M. Dockal, G. Schrenk, P. Turecek, 2014 .

IMMUNATE S/D — A new Factor VIII — von-Willebrand Factor Complex Concentrate

T. Kreil, H. Schwarz, B. Reipert, 2004 .

Quantitative determination of pectic substances as an example of a rhamnopolysaccharide assay.

F. Pittner, P. Turecek, E. Buxbaum, 1989, Journal of biochemical and biophysical methods.

Factor X Frankfurt I: molecular and functional characterization of a hereditary factor X deficiency (Gla+25 to Lys).

H. Watzke, I. Scharrer, P. Turecek, 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Involvement of low-density lipoprotein receptor-related protein (LRP) in the clearance of factor VIII in von Willebrand factor-deficient mice.

B. Binder, P. Lenting, C. Denis, 2000, Blood.

Low ADAMTS13 activity is associated with an increased risk of ischemic stroke.

A. Hofman, P. Koudstaal, M. Kavousi, 2015, Blood.

Recombinant ADAMTS13 reduces abnormally up-regulated von Willebrand factor in plasma from patients with severe COVID-19

M. Laffan, Ahilanandan Dushianthan, A. Mumford, 2021, Thrombosis Research.

Effect of High‐ versus Intermediate‐Purity Blood Coagulation Factor Concentrates on HIV‐1 Replication

M. Eibl, H. Schwarz, P. Turecek, 1996, Vox sanguinis.

The application of immobilized α-L-rhamnosidase andL-rhamnosedehydrogenase in the analysis ofL-rhamnose and α-L-rhamnosides

P. Turecek, F. Pittner, 1987 .

Simple enzyme reactors suitable for the byproduct-free preparation of the aglycones of naturally occurring glycosides under mild conditions

F. Pittner, P. Turecek, 1986 .

High Level Expression of Active Human Prothrombin in a Vaccina Virus Expression System

R. MacGillivray, F. Falkner, F. Dorner, 1992, Thrombosis and Haemostasis.

Development, Validation, and Application of a Novel Ligand-Binding Assay to Selectively Measure PEGylated Recombinant Human Coagulation Factor VIII (BAX 855).

H. Schwarz, A. Weber, P. Turecek, 2015, Bioconjugate chemistry.

GEMMA and MALDI-TOF MS of reactive PEGs for pharmaceutical applications.

G. Allmaier, M. Marchetti‐Deschmann, H. Schwarz, 2010, Journal of pharmaceutical and biomedical analysis.

MALDI linear TOF mass spectrometry of PEGylated (glyco)proteins.

G. Allmaier, P. Turecek, J. Siekmann, 2010, Journal of mass spectrometry : JMS.

Degradation of polysaccharides by immobilized depolymerizing enzymes

F. Pittner, P. Turecek, F. Birkner, 2007 .

Anti-ADAMTS13 IgG autoantibodies present in healthy individuals share linear epitopes with those in patients with thrombotic thrombocytopenic purpura

H. Rottensteiner, P. Turecek, F. Scheiflinger, 2014, Haematologica.

Visualization of a protein-protein interaction at a single-molecule level by atomic force microscopy

G. Allmaier, G. Friedbacher, H. Rottensteiner, 2014, Analytical and Bioanalytical Chemistry.

activity after infusion of desmopressin cleaving protease (ADAMTS13) - Changes in von Willebrand factor

P. Knöbl, K. Váradi, P. Turecek, 2013 .

Toll-Like Receptor Triggering Modulates Factor VIII-Specific Immune Memory in Murine Hemophilia A with Factor VIII Inhibitors.

C. Hausl, H. Schwarz, B. Reipert, 2005 .

Ca2+ concentration-dependent conformational change of FVIII B-domain observed by atomic force microscopy

G. Allmaier, G. Friedbacher, H. Rottensteiner, 2015, Analytical and Bioanalytical Chemistry.

Comparative Study on Collagen-Binding Enzyme-Linked Immunosorbent Assay and Ristocetin Cofactor Activity Assays for Detection of Functional Activity of von Willebrand Factor

H. Schwarz, P. Turecek, J. Siekmann, 2002, Seminars in thrombosis and hemostasis.

In vivo inhibition of low density lipoprotein receptor-related protein improves survival of factor VIII in the absence of von Willebrand factor.

B. Binder, H. Schwarz, P. Turecek, 2000, Blood.

Absorption, Metabolism, Distribution, and Excretion of Longer Acting rFVIII (BAX 855) Following Intravenous Administration to Rats

H. Ehrlich, H. Schwarz, B. Dietrich, 2011 .

Shear-Dependent Interactions of von Willebrand Factor with Factor VIII and Protease ADAMTS 13 Demonstrated at a Single Molecule Level by Atomic Force Microscopy.

G. Allmaier, G. Friedbacher, H. Rottensteiner, 2015, Analytical chemistry.

Modification of rVWF with Polysialic Acid: Biochemical and Functional Characterization in Mice with VWD.

H. Schwarz, H. P. Matthiessen, A. Weber, 2006 .

Biochemical and Functional Characterization of a Serum-Free rVWF Drug Candidate.

M. Purtscher, H. Schwarz, H. P. Matthiessen, 2006 .

A bio-inspired method for direct measurement of local wall shear rates with micrometer localization using the multimeric protein von Willebrand factor as sensor molecule.

G. Allmaier, G. Friedbacher, H. Rottensteiner, 2017, Biomicrofluidics.

Changes in von Willebrand factor-cleaving protease (ADAMTS13) activity after infusion of desmopressin.

P. Knöbl, K. Váradi, P. Turecek, 2003, Blood.

The 1st International Standard for von Willebrand Factor Concentrate: More to Come?

H. Schwarz, B. Ewenstein, P. Turecek, 2002, Thrombosis and Haemostasis.